ALEMBIC PHARMA | ALKEM LABORATORIES | ALEMBIC PHARMA/ ALKEM LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 16.4 | 24.4 | 67.2% | View Chart |
P/BV | x | 6.5 | 5.9 | 110.8% | View Chart |
Dividend Yield | % | 0.6 | 0.8 | 71.0% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-19 |
ALKEM LABORATORIES Mar-20 |
ALEMBIC PHARMA/ ALKEM LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 664 | 2,720 | 24.4% | |
Low | Rs | 412 | 1,660 | 24.8% | |
Sales per share (Unadj.) | Rs | 208.7 | 697.9 | 29.9% | |
Earnings per share (Unadj.) | Rs | 31.0 | 96.1 | 32.2% | |
Cash flow per share (Unadj.) | Rs | 37.1 | 117.3 | 31.6% | |
Dividends per share (Unadj.) | Rs | 5.50 | 25.00 | 22.0% | |
Dividend yield (eoy) | % | 1.0 | 1.1 | 89.5% | |
Book value per share (Unadj.) | Rs | 144.2 | 515.2 | 28.0% | |
Shares outstanding (eoy) | m | 188.52 | 119.57 | 157.7% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.6 | 3.1 | 82.2% | |
Avg P/E ratio | x | 17.4 | 22.8 | 76.2% | |
P/CF ratio (eoy) | x | 14.5 | 18.7 | 77.6% | |
Price / Book Value ratio | x | 3.7 | 4.3 | 87.8% | |
Dividend payout | % | 17.7 | 26.0 | 68.2% | |
Avg Mkt Cap | Rs m | 101,461 | 261,879 | 38.7% | |
No. of employees | `000 | NA | 14.3 | 0.0% | |
Total wages/salary | Rs m | 7,467 | 15,055 | 49.6% | |
Avg. sales/employee | Rs Th | NM | 5,822.6 | - | |
Avg. wages/employee | Rs Th | NM | 1,050.5 | - | |
Avg. net profit/employee | Rs Th | NM | 802.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,347 | 83,444 | 47.2% | |
Other income | Rs m | 94 | 1,042 | 9.0% | |
Total revenues | Rs m | 39,441 | 84,486 | 46.7% | |
Gross profit | Rs m | 8,736 | 14,734 | 59.3% | |
Depreciation | Rs m | 1,152 | 2,528 | 45.6% | |
Interest | Rs m | 184 | 651 | 28.3% | |
Profit before tax | Rs m | 7,493 | 12,598 | 59.5% | |
Minority Interest | Rs m | 11 | 0 | - | |
Prior Period Items | Rs m | -93 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,568 | 1,105 | 141.9% | |
Profit after tax | Rs m | 5,844 | 11,493 | 50.8% | |
Gross profit margin | % | 22.2 | 17.7 | 125.7% | |
Effective tax rate | % | 20.9 | 8.8 | 238.5% | |
Net profit margin | % | 14.9 | 13.8 | 107.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,577 | 54,960 | 35.6% | |
Current liabilities | Rs m | 14,896 | 32,433 | 45.9% | |
Net working cap to sales | % | 11.9 | 27.0 | 44.1% | |
Current ratio | x | 1.3 | 1.7 | 77.6% | |
Inventory Days | Days | 90 | 80 | 112.8% | |
Debtors Days | Days | 45 | 72 | 62.9% | |
Net fixed assets | Rs m | 27,097 | 32,710 | 82.8% | |
Share capital | Rs m | 377 | 239 | 157.7% | |
"Free" reserves | Rs m | 26,811 | 61,368 | 43.7% | |
Net worth | Rs m | 27,188 | 61,607 | 44.1% | |
Long term debt | Rs m | 4,993 | 1,592 | 313.6% | |
Total assets | Rs m | 47,778 | 99,433 | 48.0% | |
Interest coverage | x | 41.7 | 20.4 | 204.8% | |
Debt to equity ratio | x | 0.2 | 0 | 710.5% | |
Sales to assets ratio | x | 0.8 | 0.8 | 98.1% | |
Return on assets | % | 12.6 | 12.2 | 103.3% | |
Return on equity | % | 21.5 | 18.7 | 115.2% | |
Return on capital | % | 23.6 | 21.0 | 112.6% | |
Exports to sales | % | 0 | 19.1 | 0.0% | |
Imports to sales | % | 0 | 3.0 | 0.0% | |
Exports (fob) | Rs m | NA | 15,917 | 0.0% | |
Imports (cif) | Rs m | NA | 2,483 | 0.0% | |
Fx inflow | Rs m | 19,453 | 16,061 | 121.1% | |
Fx outflow | Rs m | 6,065 | 2,483 | 244.3% | |
Net fx | Rs m | 13,388 | 13,578 | 98.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,120 | 5,851 | 138.8% | |
From Investments | Rs m | -7,556 | -7,414 | 101.9% | |
From Financial Activity | Rs m | 590 | 792 | 74.6% | |
Net Cashflow | Rs m | 1,153 | -731 | -157.7% |
Indian Promoters | % | 74.1 | 66.9 | 110.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.9 | 33.1 | 8.8% | |
FIIs | % | 9.1 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 13.9 | 0.0 | - | |
Shareholders | 49,328 | 68,381 | 72.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC PHARMA With: FULFORD INDIA VENUS REMEDIES CIPLA WOCKHARDT AUROBINDO PHARMA
Compare ALEMBIC PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More